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Abstract
Great care is generally taken in epidemiologic studies to ensure the internal validity
of causal effect estimates; however, the external validity of effect estimates, has
received considerably less attention. The causal effect in a given target population is
the average of heterogeneous subgroup effects, weighted according to the
prevalence of the subgroups in the target population. When the study sample is not
a random sample of the target population, the sample average treatment effect, even
if internally valid, cannot be expected to equal the average treatment effect in the
target population. There are several categories of choices for the target population.
The study sample may be a census of the target population; the population from
which the study sample is a random sample or from which the study sample is not a
random sample; or some other population of which, the study sample is not a subset
of the target population. The identification conditions sufficient for external validity
closely parallel the identification conditions for internal validity, namely:
conditional exchangeability; positivity; similar distributions of the versions of;
similar patterns of interference; no measurement error; and correct model
specification. The value of an effect estimate for planning purposes and decision
making will depend on the degree of departure from both internal and external
validity. If the study sample is not a random sample of the target population, direct
standardization (the g-formula or transport formula) or inverse probability
weighting can be used to estimate a causal effect in the target population.
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Epidemiology as a discipline is distinguished by its efforts to identify causes
of disease for the purpose of intervening to improve public health. Great care is
generally taken in epidemiologic studies to ensure the internal validity of causal
effect estimates,1 including the application of methods to minimize the potential for
bias due to measurement error, confounding, selection (specifically, due to missing
data, including censoring and truncation), and model misspecification. However, the
external validity of effect estimates, has received considerably less attention. For the
purposes of this discussion, we use the term external validity to refer to the
potential for an internally valid treatment (or exposure or intervention) effect
measured in a study sample to differ from the treatment effect that would have been
estimated in the population of interest2 (henceforth, the target population). External
validity encompasses generalizability and transportability, which we distinguish
below. We advance the discussion of external validity herein using a potential
outcomes framework. We enumerate a set of identification assumptions sufficient to
estimate an externally valid effect, and note the parallel between these and the
identification assumptions sufficient to estimate an internally valid effect. Finally,
we illustrate some issues regarding generalizability with a simple example and
discuss practical considerations for addressing generalizability in epidemiological
study design.

Definitions and causal framework
A well-defined causal question states the outcome(s) of interest, denoted by
𝑌; the treatments of interest, denoted by 𝐴; and the target population, of size 𝑁
3
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described by a set of characteristics denoted by W. Here, we assume variables in W
are discrete, however, all concepts are easily extended to the case of continuous W.
The causal effect of interest is a contrast (i.e., a difference or ratio) of the
distribution of potential outcomes, 𝑌(𝑎), in the target population under two
different interventions, treatments, or policies of interest, for example:
𝐸𝑇 {𝐸[𝑌(𝑎)|W]𝑃𝑇 (W)} − 𝐸𝑇 {𝐸[𝑌(𝑎′ )|W]𝑃𝑇 (W)}

(1)

where 𝑌(𝑎) denotes the outcome that a participant would have if he or she received
treatment 𝑎, and the subscript 𝑇 denotes that the set of characteristics W takes the
distribution seen in target population. This notation makes it clear that the overall
causal effect in the target population is the average of effects that are heterogeneous
according to W, with weights defined by the distribution of W in the target
population, 𝑃𝑇 (W). 𝑃𝑇 (W) is often omitted when the causal effect of interest is
written (i.e. E[𝑌(𝑎)] − E[Y(𝑎′ )]) under the implicit assumption that either 1) the
study sample is a census of the target population; 2) the study sample is a simple
random sample from the target population, i.e., the distribution of W in the study
sample, denoted 𝑃𝑠 (𝑊), is equal to 𝑃𝑇 (W) in expectation; 3) there is a distinct
target population, 𝑀, of which the study sample is not a proper subset, for which
𝑃𝑀 (W) is equal to 𝑃𝑆 (W); or 4) the causal effect is homogeneous across all 𝑊 for the
causal contrast of interest.
It is helpful to distinguish threats to validity that arise after enumeration of
the study sample, which we define as threats to internal validity, from threats to
validity due to eligibility and enrollment of study subjects, which we define as
threats to external validity. We define an estimator as internally valid when the
4
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estimator of association in the study sample is a consistent estimator of the
treatment effect in the source population from which the study participants are
randomly sampled (the sample average treatment effect). The distribution of 𝑊 in
the study sample, 𝑃𝑆 (W), may differ from 𝑃𝑇 (W) without threatening internal
validity. We define a causal estimator to be externally valid when the sample
average treatment effect is a consistent estimator of the average treatment effect in
the target population (population average treatment effect). An estimate will be
externally valid under one of the first three scenarios described above, all of which
result in the distribution of W in the study sample being equal to the distribution of
W in the target population.

Assumptions
Given we cannot observe all potential outcomes for subjects in our target
population or our study sample,3,4 we can rely on a sufficient set of identification
assumptions under which (with a consistent estimator) an estimate of association
could be interpreted causally.
These assumptions are well described in the literature for estimating an
internally valid causal estimate. They include: 1) the unexposed are a good
substitute for the experience of the exposed in the absence of exposure and vice
versa (exchangeability), perhaps conditional on a set of covariates, Z (conditional
exchangeability); 2) a non-zero probability of exposure within every stratum
defined by Z (positivity); 3) treatment variation irrelevance or no versions of
treatment (sometimes referred to as consistency);5-84) no interference or partial
5
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interference (or some other restriction on the interference structure);9,10 5) no
measurement error; and 6) if Z is high dimensional and non-parametric inference is
unfeasible, correct specification of parametric models.
The identification conditions sufficient for external validity closely parallel
the identification conditions for internal validity.18,27 First, we assume that the
participants included in the sample are exchangeable with members of the target
population who were not sampled, perhaps conditional on W (conditional
exchangeability):
𝑆 ⊥ [𝑌(𝑎), 𝑌(𝑎′ )]|W
where 𝑆 is an indicator of enrollment into the study sample. Enrollment into the
sample is both under the control of the researcher (in designing a recruitment
strategy) and under the control of the participants (in deciding whether to provide
consent to participate). For the purposes of identification of the causal contrast in
the target population, the set of characteristics, 𝑊, is sufficient if it includes all
causes of (or proxies for causes of) sampling and the outcome. If the researcher is
willing to specify a single causal contrast of interest, then the set of characteristics
W may be restricted to a subset of W that are effect measure modifiers of that
contrast.2 Second, we assume that, within strata of W, all subjects in the target
population have some probability of being selected into the sample (𝑆 = 1)
(positivity):
0 < Pr(S = 1|W) < 1, for all W, such that 𝑃𝑇 (W) > 0
Third, we assume similar distribution of the versions of treatment in the study
sample and the target population (of which treatment variation irrelevance is a
6
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special case). This may be a strong assumption when the delivery mechanism for
treatment differs dramatically between the study sample and the target population
(e.g., treatment given to trial participants may have been accompanied by more
adherence education and supportive services, as well as Hawthorne effects due to
trial participation).11 Fourth, we assume similar patterns of interference in the
target population and the study sample (of which no interference is a special
case).11-13 Finally, we assume no measurement error for exposure, outcome, and all
variables W, and correct model specification (if we use a parametric model ).

Defining the target population
Failure to specify the target population explicitly precludes comparisons
between the target population and the study sample of patient characteristics
(exchangeability), details of the implementation of the intervention (treatment
versions), or the comparison of patterns of interference between the target
population and the study sample. In failing to make these aspects explicit in study
design and planning, the generalizability of study results to some unspecified target
population is nebulous.14-18
There are several categories of choices for the target population.19 First, the
study sample may be a census of the target population. This is almost never the case,
because in nearly all instances, we have done research to inform decisions about a
population at least somewhat different than that under study. A second choice for
the target population may be the population from which the study sample was
sampled. When the sampling is random, 𝑃𝑆 (W) is the same as 𝑃𝑇 (W) in expectation
7
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and sample average treatment effect equals the population average treatment effect
in expectation (Figure 1a). When the study sample is not a random sample from the
target population and 𝑃𝑆 (W) differs from 𝑃𝑇 (W), the sample average treatment
effect can be expected to differ from the population average treatment effect (Figure
1b). A third choice for the target population is some other population that does not
include the study sample (Figure 1c). In both of the latter cases (study sample not a
random sample of the target; external population), additional information is needed
to estimate the effect of interest in the target population, namely the distribution of
𝑃𝑇 (W).
A distinction between generalizing results to a target population that
includes as members those persons included in the study sample (Figures 1a and
1b) and transporting results to a target population that is non-overlapping with the
study sample (Figure 1c) has been made previously, but not discussed in depth. 20 In
the former case, a physical probability of sampling can be envisioned;21 in the latter,
the probability of sampling is not physical.21,22 This should not alarm us;
transporting results to a target population that is non-overlapping with the study
sample is simply direct standardization. Graphical criteria can assist in determining
whether an estimate of effect is directly transportable and if not, can help identify
the appropriate “transport formula” for estimating an effect for the target
population.23,24 Despite these distinctions between target populations are
overlapping or non-overlapping with the study sample, the same set of
generalizability assumptions described above holds in both scenarios.

8
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Example
To demonstrate how the sample average treatment differs from the
population average treatment effect when the study sample is not a random sample
of the target population, consider the following example. Imagine the target
population comprises 𝑁 = 50,000 individuals, in whom the prevalence of two
dichotomous causes of the outcome, 𝑊1 and 𝑊2, is 0.15 and 0.20, respectively. In the
study sample (𝑛=1,000), as in many trials, participants at greater risk of the
outcome (𝑊1 = 1 or 𝑊2 = 1) were oversampled, with 𝑃(𝑊1) = 0.5 and 𝑃(𝑊2 ) = 0.5.
In both the study sample and in in the target population, the exposure, 𝐴, is
randomly assigned with probability 0.5. The 1-year risk for the outcome is defined
by the function: 𝑃(𝑌 = 1) = 0.1073 − 0.05𝐴 + 0.20𝑊1 + 0.20𝑊2 − 0.15𝐴𝑊1𝑊2. The
data from one realization of a target population and study sample generated under
these conditions appears in Table 1.
Given this realization of the data, the estimate of the risk difference due to 𝐴
in the target population is -5.3%. The estimate of the risk difference due to 𝐴 in the
study sample is -9.7%.
The g-formula or inverse probability (IP) of sampling weights can be used to
use the study sample data to estimate the population average treatment effect. The
g-formula (equivalent to Bareinboim & Pearl’s “transport formula”)23 and equation
(1) above is:
𝑃[𝑌(𝑎)] = ∑ 𝑃[𝑌(𝑎)|𝑊 = 𝑤]𝑃𝑇 (𝑊 = 𝑤)
𝑊
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Which, if we assume consistency and conditional exchangeability given 𝑊, can be
estimated by:
𝑃[𝑌 = 1|𝐴 = 𝑎] = ∑ 𝑃[𝑌 = 1|𝐴 = 𝑎, 𝑊 = 𝑤]𝑃𝑇 (𝑊 = 𝑤)
𝑊

where the quantity 𝑃[𝑌 = 1|𝐴 = 𝑎, 𝑊 = 𝑤] is estimated in the study sample and
𝑃𝑇 (𝑊 = 𝑤) is the probability that 𝑊 = 𝑤 in the target population. The estimate of
effect in the target population using the non-parametric g-formula was -5.4%.
Scaled IP of sampling weights were defined:
𝑃(𝑆 = 1)
𝑃(𝑆 = 1|𝑊1 = 𝑤1 , 𝑊2 = 𝑤2 )
If the set of covariates, 𝑊, that should be included in calculating IP of sampling
weights is high dimensional, the denominator of the weights can be modeled
parametrically. In this example, we used a fully saturated model for the
denominator of the weights. The IP of sampling weighted estimate of effect in the
target population based on data from the study sample was -5.4%.

Note that the results from the IP of sampling approach and the gformula/transport formula will be equivalent when both are estimated nonparametrically. In practice, if the dimension of 𝑊 is large and 𝑃(𝑆 = 1) or 𝑃(𝑌 =
1|𝐴 = 𝑎, 𝑊 = 𝑤) is modeled, the two approaches may give different results due to
different modelling assumptions or model misspecification. Doubly robust
estimation of the population average treatment effect is also possible. 25

Practical considerations for study design
10
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The only way to ensure an estimate is directly generalizable (in expectation)
to a particular target population would be draw the study sample as a random
sample from that target population as described above.12 However, beyond the
logistical, financial, and ethical challenges to conducting such a study, in certain
circumstances, a study sample that is representative of the target population may be
undesirable.18,26,27 When first exploring the existence of a causal effect, non-random
sample selection may be purposefully undertaken. For example, an investigator
might enroll a sample for a trial that has a higher than average risk of disease to
increase statistical efficiency, or restrict enrollment into an observational study to
control for an important confounder. Oversampling to avoid sparse numbers of
patients within subgroups improves precision during confounder control and also
allows estimation of subgroup effects,18,26 although trials are rarely powered to
estimate such subgroup effects.
Epidemiologists are typically primarily concerned with the internal validity
of effect estimates. However, the value of an effect estimate for planning purposes
and decision making will depend on the degree of departure from both internal and
external validity. External validity will be threatened to the degree that 1) the
prevalence of other causes of the outcome (also versions of treatment, patterns of
interference) differs in the study sample and the target population, and 2) the
exposure or intervention causal contrast is modified by those other causes of the
outcome that differ in the study sample and the target population.2 For example,
Greenhouse et al., describe a trial of antidepressants in adolescents that pointed to
an increased risk of suicide, but which excluded participants with the most severe
11
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depression who would have experienced the greatest benefits from the therapy. 15 In
this case, while the trial effects were internally valid, the lack of external validity had
serious implications for policy and removed potentially beneficial treatment options
from depressed adolescent patients. A second example is, the discrepancies between
the conclusions about the effects of combined estrogen/progestin menopausal
hormone replacement therapy (HRT) on coronary heart disease based on the
Women’s Health Initiative trial and the Nurses’ Health Study can be recast as a
generalizability problem if we consider that the age- and time-on-exposure stratum
specific effects of HRT estimated in both studies were similar,28 but the distribution
of women by age and time-on-exposure in the target population (young women with
no prior exposure) did not match the distribution of women in the study sample
from the Nurses’ Health Study (older women with lots of prior exposure). In this
instance, while internal validity (confounding by some unmeasured factor) was
initially blamed for the discrepancy, and while generalizability is typically only
thought of as an issue for clinical trials, the generalizability of this observational
study undermined policy recommendations based on its results. Such examples
highlight the importance of balancing study design decisions to maximize both
internal and external validity.
If our study sample is not a random sample of the target population, we can
estimate causal effects in a specified target population using direct standardization
or inverse probability weighting (a semiparametric extension of direct
standardization)29 if all predictors of both selection into the study sample and the
outcome are measured in both the study sample and the target population. This
12
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methodological solution would allow us to use a single study sample to calculate
generalized estimates of effect for multiple different specified target
populations2,12,13 as long as the distribution of W was available for the target
population.15,30

Discussion
Commentaries on the lack of generalizability of randomized trials typically
implore the reader to evaluate a lengthy check list of potential determinants of
external validity,16,17,31 or further classify the list into categories to distinguish
“external validity” from “applicability.”32 We argue that such exercises could be
more efficient if considered quantitatively, within the potential outcomes
framework. This approach would quickly narrow the scope of future research
needed to ascertain the effect estimate of interest because specific threats to the
external validity of the estimate could be identified and used to guide future study
design. Furthermore, understanding the mechanism by which differences between
the sample and the target population influence the generalizability of a sample
estimate would help identify the most appropriate methods to account for those
differences. Understanding differences in the distribution of risk factors for the
outcome has implications for the selection of the study sample for future research.
Arguments about the generalizability of study results are not well-formed
until the relevant characteristics of the target population are explicitly stated (i.e.,
patient characteristics are designated or interference patterns are specified or the
types of therapy defined). This is analogous to the estimation of controlled direct
13
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effects; such direct effects are not well-defined until the researcher specifies that the
estimator is the direct effect not through M, where M is some possible mediator.33
Finally, distinguishing internal and external threats to validity is useful for
determining which parameters in the study sample or target population are
estimable. When collider stratification bias due to selection is present in a study, it
may threaten causal inference being made for any population, 34 even the study
sample, and preclude attempts to generalize results to either the source population
or any specified target population (associational estimate is biased for the causal
effect in the study sample; generalizability is irrelevant). In contrast, if a study can
be determined to be free of selection bias (and confounding) (associational estimate
is an unbiased estimate of the causal effect in the study sample) and differences in
average treatment effects attributed to nonrandom sampling of the study
population, methods exist to generalize results to a the target population
(contingent on all assumptions outlined above).2,35 Standardizing effect estimates to
the appropriate target population will improve their utility to clinicians and public
health practitioners, and better inform implementation of interventions in target
populations.
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Table 1. Data from a hypothetical target population (𝑁=50,000) and nonrandom
study sample (𝑛=1,000)
𝑍1

𝑍1

𝐴

𝑌

N (target)

0
0
0
0
15,023
0
0
0
1
1807
0
0
1
0
16,046
0
0
1
1
1,035
0
1
0
0
2,954
0
1
0
1
1,285
0
1
1
0
3,221
0
1
1
1
1,078
1
0
0
0
2,087
1
0
0
1
914
1
0
1
0
2,285
1
0
1
1
787
1
1
0
0
360
1
1
0
1
378
1
1
1
0
517
1
1
1
1
223
a Scaled inverse probability of sampling weight

n
(sample)
68
11
75
6
85
35
91
29
88
28
88
36
84
97
125
54

Scaled IP Weighted
sampling sample
weighta
4.239
288.2
4.239
46.6
4.239
317.9
4.239
25.4
0.712
60.5
0.712
24.9
0.712
64.7
0.712
20.6
0.506
44.5
0.506
14.2
0.506
44.5
0.506
18.2
0.082
6.9
0.082
8.0
0.082
10.3
0.082
4.4
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Table 2. Summary data from a hypothetical target population (𝑁=50,000) and crude
and inverse probability of sampling weighted nonrandom study sample (𝑛=1,000)
Target population
Y=0
Y=1
Risk
X=0 20,424 4,384 0.177
X=1 22,069 3,123 0.124
RD:
-0.053
RR:
0.702

X=0
X=1
RD:
RR:

Study sample
Y=0 Y=1 Risk
325 171 0.345
379 125 0.248
-0.097
0.719

X=0
X=1
RD:
RR:

Weighted sample
Y=0 Y=1 Risk
400 94 0.190
437 69 0.136
-0.054
0.716
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Figure 1. Possible choices for the target population of interest
1a:

1b:

1c:

The target population (large, light gray square) can relate to the study sample
(small, dark gray circle) in multiple ways. (a) The study sample is a random sample
from the target population. (b) The study sample is not a random sample from the
target population. (c) The target population is external to the study sample. The
target population can be described by either a census of the target population or a
random sample of the target population (small, dark gray square). In situation (b) or
(c), the study sample can be thought of as a random sample from a larger superpopulation (larger, light gray circle) that differs from the target population; if the
analysis does not standardize or transport results to the target population, inference
is restricted to this super-population.
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